Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Pathogenesis of Charcot-Marie-Tooth 1A (CMT1A) neuropathy.

Trends in neurosciences - 1 Jul 1998

Hanemann C O, Müller H W

Abstract excerpt

The hereditary neuropathy Charcot-Marie-Tooth (CMT) type 1A is, in the majority of cases, caused by duplication of the gene for the peripheral myelin protein PMP22, which leads to abnormally increased PMP22 expression. Recent in vitro and in vivo data indicate a novel function of PMP22 in Schwann-cell growth and differentiation other than its role in myelination, and suggest that overproduction of PMP22 leads to...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cell Differentiation
Share to Charcot-Marie-Tooth Disease
Share to Gene Expression Regulation

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to PMP22 gene

Share to Multigene Family

Share to Myelin Proteins

Share to Phenotype

Share to Schwann Cells

Source

Identifiers

PMID: 9683317
DOI: 10.1016/s0166-2236(97)01222-8

Genes

PMP22

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Pathogenesis of Charcot-Marie-Tooth 1A (CMT1A) neuropathy.PMID 9683317Read ↗

Charcot-Marie-Tooth disease type 1A: mutational mechanisms and candidate gene.Semantic proximity Read ↗

Disease mechanisms and potential therapeutic strategies in Charcot-Marie-Tooth disease.Semantic proximity Read ↗

CMT1A current gene therapy approaches and promising biomarkersSemantic proximity Read ↗

[Molecular pathology of Charcot-Marie-Tooth disease type 1A: abnormal expression of PMP-22].Semantic proximity Read ↗

PMP22 expression in dermal nerve myelin from patients with CMT1ASemantic proximity Read ↗

Charcot-Marie-Tooth disease type 1: molecular pathogenesis to gene therapy.Semantic proximity Read ↗

Molecular mechanisms, diagnosis, and rational approaches to management of and therapy for Charcot-Marie-Tooth disease and related peripheral neuropathies.Semantic proximity Read ↗

Charcot-Marie-Tooth disease and pathways to molecular based therapies.Semantic proximity Read ↗

Charcot-Marie-Tooth Disease and Related Inherited NeuropathiesSemantic proximity Read ↗

Mutation-dependent alteration in cellular distribution of peripheral myelin protein 22 in nerve biopsies from Charcot–Marie–Tooth type 1ASemantic proximity Read ↗

Many facets of the peripheral myelin protein PMP22 in myelination and disease.Semantic proximity Read ↗

Navigating the Landscape of CMT1B: Understanding Genetic Pathways, Disease Models, and Potential Therapeutic Approaches.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.